Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

February 15, 2022

Study Completion Date

February 15, 2022

Conditions
Lower Urinary Tract SymptomsBladder CarcinomaBCG
Interventions
DRUG

Pentosan Polysulfate Na 100Mg Cap

"Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."

DRUG

Placebo oral capsule

"Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."

Trial Locations (1)

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cancer Research Network

OTHER

lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER

NCT03549650 - Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | Biotech Hunter | Biotech Hunter